Citation Impact
Citing Papers
Global Cancer Incidence and Mortality Rates and Trends—An Update
2015 Standout
Hepatitis C virus drug resistance–associated substitutions: State of the art summary
2015
Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies
2018 StandoutNobel
Cancer Statistics, 2021
2021 Standout
Regulation of microRNA function in animals
2018 Standout
Antiviral Resistance and the Future Landscape of Hepatitis C Virus Infection Therapy
2013
Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks
2015
SEC14L2 enables pan-genotype HCV replication in cell culture
2015 StandoutNatureNobel
HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape
2018
Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents
2013
From non-A, non-B hepatitis to hepatitis C virus cure
2015
Multi-input chemical control of protein dimerization for programming graded cellular responses
2019 StandoutNobel
The importance of resistance to direct antiviral drugs in HCV infection in clinical practice
2015
Resistance Analysis of Hepatitis C Virus Genotype 1 Prior Treatment Null Responders Receiving Daclatasvir And Asunaprevir
2013
Hepatitis C
2015
Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir
2016 StandoutNobel
Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection
2016
A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors
2019 StandoutNobel
The role of resistance in HCV treatment
2012
Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial
2015
Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection
2018
Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients
2015
Successes and Challenges on the Road to Cure Hepatitis C
2015
Treatment of hepatitis C in difficult-to-treat patients
2015
Update on hepatitis C virus resistance to direct-acting antiviral agents
2014
Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection
2016
Antiviral therapy of hepatitis C in 2014: Do we need resistance testing?
2014
Hepatitis C Virus: 30 Years after Its Discovery
2019 StandoutNobel
Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens
2016
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
2014 Standout
Host – hepatitis C viral interactions: The role of genetics
2016
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
2013 StandoutNobel
Taming a beast: lessons from the domestication of hepatitis C virus
2019 StandoutNobel
Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients
2017
Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus
2015
Protease inhibitor therapy for hepatitis C virus-infection
2018
NS5B polymerase inhibitors in phase II clinical trials for HCV infection
2017
Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection
2015
Discovery and Development of Simeprevir (TMC435), a HCV NS3/4A Protease Inhibitor
2014
Stereoselective Enzymatic Synthesis of Heteroatom-Substituted Cyclopropanes
2018 StandoutNobel
Virologic Tools for HCV Drug Resistance Testing
2015
Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical Implications
2015
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection
2017
A Comprehensive Computational Analysis for the Binding Modes of Hepatitis C Virus NS5A Inhibitors: The Question of Symmetry
2016 StandoutNobel
Screening for Hepatitis C Virus Infection in Adolescents and Adults
2020
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
2018 Standout
EASL Recommendations on Treatment of Hepatitis C 2018
2018 Standout
Viral persistence, liver disease, and host response in a hepatitis C–like virus rat model
2017 StandoutNobel
Replicons of a Rodent Hepatitis C Model Virus Permit Selection of Highly Permissive Cells
2019 StandoutNobel
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Perspectives on HCV: Current Therapeutic Regimens and Drug–Drug Interactions
2017
Internal Disequilibria and Phenotypic Diversification during Replication of Hepatitis C Virus in a Noncoevolving Cellular Environment
2017 StandoutNobel
Ultrasound Elastography: Review of Techniques and Clinical Applications
2017 Standout
New therapeutic strategies in HCV: second‐generation protease inhibitors
2013
Barrier-Independent, Fitness-Associated Differences in Sofosbuvir Efficacy against Hepatitis C Virus
2016 StandoutNobel
Importance of HCV genotype 1 subtypes for drug resistance and response to therapy
2014
Works of Bart Fevery being referenced
Virologic response and characterisation of HCV genotype 2–6 in patients receiving TMC435 monotherapy (study TMC435-C202)
2012
TMC435 IN COMBINATION WITH PEGINTERFERON ALPHA-2A/RIBAVIRIN IN TREATMENT-NAiVE PATIENTS INFECTED WITH HCV GENOTYPE 1: VIROLOGY ANALYSIS OF THE PILLAR STUDY
2011
Amplification and Sequencing of the Hepatitis C Virus NS3/4A Protease and the NS5B Polymerase Regions for Genotypic Resistance Detection of Clinical Isolates of Subtypes 1a and 1b
2013
Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4
2015
Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies
2014
Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region
2015
Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1‐infected patients without cirrhosis: OPTIMIST‐1, a phase 3, randomized study
2016
LP04 : A phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: Optimist-2
2015
LP14 : A phase 3, randomised, open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: Optimist-1
2015
In Vitro Activity of Simeprevir against Hepatitis C Virus Genotype 1 Clinical Isolates and Its Correlation with NS3 Sequence and Site-Directed Mutants
2015
Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST‐2)
2015
In vitro virology profile of the 3 direct-acting antiviral combination of AL-335, odalasvir and simeprevir
2017
9 TMC435 IN PATIENTS INFECTED WITH HCV GENOTYPE 1 WHO HAVE FAILED PREVIOUS PEGYLATED INTERFERON/RIBAVIRIN TREATMENT: VIROLOGIC ANALYSES OF THE ASPIRE TRIAL
2012
Development and evaluation of an automated hepatitis C virus NS5B sequence-based subtyping assay
2010